Moleculin Biotech, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| CVI Investments, Inc. | 9.9% | 1,863,377 | SCHEDULE 13G, 2026-08-10 | 2026-07-31 |
| Klemp Walter V | 9.9% | 2,070,761 | SCHEDULE 13D, 2026-08-25 | 2026-08-19 |
| Foster Jonathan P. | 6.3% | 1,288,207 | SCHEDULE 13D, 2026-08-25 | 2026-08-19 |
| Armistice Capital, LLC | 4.99% | 1,586,521 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Mitchell P. Kopin | 4.99% | 973,927 | SCHEDULE 13G, 2026-08-06 | 2026-07-31 |
Purpose of Transaction (Item 4)
Klemp Walter V
On August 3, 2026, Mr. Klemp purchased 533,333 shares of Common Stock and Common Warrants to purchase up to 1,599,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Persons reserve the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, market conditions or other factors. Except as set forth in this Schedule 13D, the Reporting Persons do not have any plan or proposal that would relate to, or result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-25; the filing has the rest
Foster Jonathan P.
On August 3, 2026, the Reporting Person purchased 293,333 shares of Common Stock and Common Warrants to purchase up to 879,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Person reserves the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Person, market conditions or other factors. Except as set forth in this Schedule 13D, the Reporting Person does not have any plan or proposal that would relate to, or result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-25; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-08-06 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-08-10 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2026-08-25 | Klemp Walter V | 9.9% | SCHEDULE 13D |
| 2026-08-25 | Foster Jonathan P. | 6.3% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Moleculin Biotech, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.